FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN)...
Vous n'êtes pas connecté
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN)...
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a...
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data...
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data...
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular...
NORTH CHICAGO, Ill., June 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food...
AbbVie (ABBV) issues the second CRL for Parkinson's disease medicine, ABBV-951, based on some observations on inspection of one of its third-party...
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1...
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails...
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates,...